Status:
COMPLETED
Characterization and Clinical Outcomes of Severe Asthma Patients in Israel Treated With Benralizumab (SAIL-B)
Lead Sponsor:
AstraZeneca
Conditions:
Severe Asthma
Eligibility:
All Genders
Brief Summary
A retrospective, observational, one arm, single country study, using the computerized database of Maccabi Health Services (MHS). The study will include adult patients who initiated benralizumab treatm...
Eligibility Criteria
Inclusion
- An authorization from MHS drugs authorization center for benralizumab, with a diagnosis of asthma (ICD-9 code 493.X and the corresponding internal MHS diagnosis codes for SA). Having an authorization indicates that patients have severe eosinophilic asthma and fulfil the GINA definition of severe asthma as well as additional local reimbursement criteria.
- At least one purchase of benralizumab for the first time between January 1 2019 and March 31 2024.
- Age ≥18 years on the index date.
- MHS members for at least 12 months before the index date.
Exclusion
- • Patients who received benralizumab for indication other than asthma according to MHS drugs authorization center.
- \- currently or recently included in a clinical trial according to the ICD-9 diagnosis code V70.7) and the corresponding internal MHS codes
Key Trial Info
Start Date :
March 24 2025
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 24 2025
Estimated Enrollment :
197 Patients enrolled
Trial Details
Trial ID
NCT07218172
Start Date
March 24 2025
End Date
April 24 2025
Last Update
October 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Tel Aviv, Israel